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Background: Hearing loss is the most common sensory deficit in humans, affecting approximately 10% of the global
population. In developed countries, one in every 500 individuals suffers from severe to profound bilateral sensorineural
hearing loss. For those up to 5 years old, the proportion is higher, at 2.7 in 1000 individuals, and for adolescents the
average is 3.5 in 1000. Among the causes of hearing loss, more than 50% are related to genetic factors. To date, nearly
150 loci and 64 genes have been associated with hearing loss. Mutations in the GJB2 gene, which encodes connexin 26,
constitute the main genetic cause. So far, more than 300 variations have been described in this gene.
As a response to the clinical and genetic heterogeneity of hearing loss and the importance of correct molecular
diagnosis of individuals with hereditary hearing loss, this study worked in the optimization for a diagnostic
protocol employing a high-throughput genotyping technology.
Methods: For this work, was used the TaqMan® OpenArray™ Genotyping platform. This is a high performance,
high-throughput technology based on real-time PCR, which enables the evaluation of up to 3072 SNPs (Single
Nucleotide Polymorphisms), point mutations, small deletions, and insertions, using a single genotyping plate. For
the study, were selected the layout allowing to analyze 32 alterations in 96 individuals simultaneously. In the end, the
generated results were validated by conventional techniques, as direct sequencing, Multiplex PCR and RFLP-PCR.
Results: A total of 376 individuals were analyzed, of which 94 were healthy controls, totaling 4 plates in duplicate.
All 31 of the changes analyzed were present in the nuclear genes GJB2, GJB6, CRYL1, TMC1, SLC26A4, miR-96, and
OTOF, and in the mitochondrial genes MT-RNR1 and MT-TS1. The reactions were subsequently validated by
established techniques (direct sequencing, multiplex PCR, and RFLP-PCR) that had previously been used to perform
molecular screening of hearing loss at the Human Genetics Laboratory of the Center for Molecular Biology and
Genetic Engineering (CBMEG), at the State University of Campinas (UNICAMP). In total, 11,656 genotyping reactions
were performed. Of these, only 351 reactions failed, representing approximately 3.01% of the total. The average
accuracy of genotyping using the OpenArray™ plates was 96.99%.
Conclusions: The results demonstrated the accuracy, low cost, and good reproducibility of the technique,
indicating that the TaqMan® OpenArray™ Genotyping Platform is a useful and reliable tool for application in
molecular diagnostic testing of hearing loss.
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Hearing loss is the most common sensory deficit in
humans. It can restrict oral skills and cause changes in
cognitive and psychological development. A study
undertaken in 2013 showed that at least 360 million
people, corresponding to more than 5% of the global
population, have disabling hearing loss (loss exceeding
40 dB in adults or 30 dB in children) [1].
One in every 500 children has severe to profound con-
genital bilateral deafness. For children up to 5 years of age,
this number rises to 2.7 per 1000 children, and for adoles-
cents the number is 3.5 per 1000 individuals. In the case
of unilateral profound deafness, the number of children
affected is 3–6 in every 1000, and 2–4 out of 1000 chil-
dren will be deaf before adulthood (post-lingual deafness).
These deafness rates can vary according to location [2-4].
Hearing impairment can have congenital or acquired
causes. Congenital hearing loss affects individuals who are
born with the loss, or acquire it shortly after birth. It is
caused by genetic factors such as changes in one or more
genes, or in regulatory mechanisms that are involved in
the proper development, structure, and function of the
ear. Acquired hearing loss occurs in the auditory system
due to injuries that occur during life, such as frequent ex-
posure to high intensity sound, acoustic trauma, infections,
and ototoxic drugs, amongst other causes (Table 1) [1].Table 1 Main causes of hearing loss





























Source: adapted from [5].In Brazil, 66.7% of cases of hearing loss are caused by
environmental factors, while 18.5% are of unknown eti-
ology and 14.8% are classified as being due to genetic in-
heritance [6].
Studies have shown that in developed countries at
least 50% of all problems related to congenital deafness
are hereditary, with 70% of these cases classified as non-
syndromic hearing loss (NSHL), where the deafness is
an isolated symptom. The remaining 30% of cases are
due to syndromic hearing loss (SHL), which is associated
with other symptoms or abnormalities in addition to
deafness, including malformations, vision problems,
renal, thyroid, cardiac dysfunctions, etc. [7-9].
Non-syndromic hearing loss is divided into different
subtypes according to the inheritance pattern: autosomal
dominant (DFNA, 20%), autosomal recessive (DFNB,
80%), X-linked (DFNX, <1%), Y-linked (DFNY, <1%), and
mitochondrial (less than 1%) [10-13].
To date, more than 64 genes have been reported in
150 loci related to hearing loss, and it is estimated that
the number of genes could reach 300, equivalent to 1%
of all human genes [3,14].
More than 134 loci are associated with non-syndromic
hearing loss, and the most common mutations are found
in the GJB2 gene (which encodes the connexin 26 pro-
tein), accounting for over 50% of all cases of non-
syndromic hearing loss and 10-20% of all cases of pre-
lingual hearing loss in developed countries [14].
Among some others main genes related to Non-
Syndromic Hearing Loss are the SLC26A4, OTOF and
TMC1 genes. Alterations in the SLC26A4 gene are re-
sponsible to make it as the second most frequent cause of
ARNSHL (Autosomal Recessive Non-Syndromic Hearing
Loss). For each of these genes, excluding the GJB2 who
already have knowledge of more than 300 alterations,
there are at least 20 changes already reported [15,16].
As indicated above, many genes and mutations are re-
lated to hearing loss of genetic origin. There is therefore a
need for in-depth investigations to diagnose and attribute
mutations detected in earlier tests, enabling a better under-
standing of the molecular mechanisms of hearing loss in
individuals with unknown etiology and a correct treatment.
Direct sequencing is widely used, but has drawbacks in
that it is expensive, time-consuming, and inefficient for
the sequencing of large fragments. Variations of the PCR
(Polymerase Chain Reaction) technique have been tested
as cheaper options for the detection of the main mutations
associated with the disease under investigation. However,
these techniques have also shown severe limitations in
terms of their diagnostic applicability. Independent of the
particular variant of the technique, PCR results are mostly
individual, or generate one result per reaction (excluding
the Multiplex PCR), resulting in the process becoming ex-
pensive and unfeasible due to the cost of reagents [15].
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it possible to perform multiple simultaneous experiments,
which could help to elucidate the etiology of different
cases of hearing loss. These new technologies use only
small volumes of samples and reagents in the reactions,
and combine high accuracy with simplicity. A fewer num-
ber of steps, together with automation using pipetting sta-
tions, decreases both the time required for development
of the experimental phase and the likely errors associated
with manual pipetting, allowing several tests to be per-
formed simultaneously at low cost [17].
In view of the clinical and genetic heterogeneity of hear-
ing loss and the importance of correct molecular diagnosis
of individuals with hereditary hearing loss, this paper pro-
poses the optimization of a diagnostic protocol that uses a
high-throughput genotyping technology based on real-
time PCR, known as the TaqMan® OpenArray™ Genotyp-
ing Platform (Life Technologies). To this end, a genotyping
plate was developed that enabled the simultaneous analysis
of 32 changes in 96 individuals, using a single plate.
Methods
Casuistry
The 376 samples selected had been referred to the Human
Molecular Genetics Laboratory of the Center for Molecular
Biology and Molecular Engineering (CBMEG) by different
organizations in order to determine the etiology of the
hearing loss. Of these individuals, 86 of them were used as
negative and positive controls, presenting previous resultsFigure 1 Representation of the OpenArray™ plate. This contains 48 sub
wells, each with a volume of 33 nL.for the GJB2 gene and/or the GJB6 gene, and for the mito-
chondrial mutation m.1555A >G in the MT-RNR1 gene. A
total of 94 controls with normal hearing were employed.
This project was approved by the Research and Ethics
Committee of the Faculty of Medical Sciences, UNICAMP,
under protocol No. 396/2006. All the volunteers who par-
ticipated in this work had previously signed informed con-
sent forms, after having received an explanation of the
intended investigation.
The TaqMan® OpenArray™ Genotyping Platform
The TaqMan® OpenArray™ Genotyping platform (Applied
Biosystems, USA) is a high performance, high-throughput
technology based on real-time PCR, which enables the
evaluation of up to 3072 SNPs, point mutations, small dele-
tions, and insertions, using a single genotyping plate. This
platform also allows 2688 gene expression assays to be per-
formed per plate. The platforms for genotyping and gene
expression must conform to a default layout test offered by
the company [18]. Based on hydrolysis of the TaqMan®
probes, the TaqMan® OpenArray™ Genotyping technique
requires a pair of primers common to both wild-type and
the mutant sequences, as well as two different MGB (Minor
Groove Binder) probes for each assay, one being a probe
for the normal sequence, labeled with the VIC® fluorophore,
and the other being a probe for the mutant sequence, la-
beled with the FAM® fluorophore.
The plates used in the OpenArray™ assays were com-
posed of 48 sub-arrays (4.5 mm× 4.5 mm), each with 64-arrays, highlighting the arrangement of a sub-array with 64 nano-
Table 2 List of 32 alterations analyzed using the








c.283G > A p.V95M [19]
c.339 T > G p.S113R [19]
c.279G > A p.M93I [20]
c.286G > A p.W24X [21]
c.439G > A p.E147K [15]
c.617A > G p.N206S [22]
c.385G > A p.E129K [22]
c.109G > A p.V37I [19]
c.269 T > C p.L90P [23]
c.550C > G p.R184W [24]
c.551G > C p.R184P [25]
c.516G > A p.W172X [15]
c.224G > A p.R75Q [15]
c.101 T > C p.M34T [26]
c.457G > A p.V153I [15]




GJB6 (ID 10804) c.6013G > T
OTOF (ID 9381) c.2485C > T p.Q829X [28]
miR96 (ID 407053)
c.13G > A [29]
c.14C > A [29]
TMC1 (ID 117531) c.1939 T > C p.S647P [30]
CRYL1 (ID 51084) c.1622 T > C
MT-TS1 (ID 4574) m.7445A > G [31]
MT-RNR1 (ID 6775087)
m.1555A > G [32]
m.827A > G [33]
m.1494C > T [34]
SLC26A4 (ID 5172)
c.445G > A p.G149R [35]
c.1238A > G p.Q413R [35]
c.1826 T > G p.V609G [36]
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phobic properties, while the interior of the wells (where the
probes and primers needed for the reactions were already
installed) were hydrophilic in nature. These physical prop-
erties enabled small volumes (33 nL) of sample to be deliv-
ered with great accuracy and precision [18].
The platform consisted of a pipetting system (OpenArray™
AccuFill® System) (Applied Biosystems), connected to a
computer that controlled all the operations by means of the
manufacturer’s proprietary software. The platform also in-
cluded a Flat Dual Block 9700 GeneAmp® PCR System ther-
mocycler (Applied Biosystems), suitable for cycling the
OpenArray™ plates, a sealing station, and an OpenArray™
NT Cycler®, which was responsible for capturing the fluor-
escence emitted from the plate. This last item of equipment
was also controlled using the same OpenArray™ Genotyper
software.
DNA genomic extraction
The genomic DNA was extracted from leukocytes
present in 10–15 mL of peripheral blood, collected in Va-
cutainer tubes containing 10% 0.5 M EDTA (ethyl-
enediaminetetraacetic acid, disodium dihydrate salt)
at pH 8.0. The extraction was performed using a stan-
dardized phenol-chloroform method developed at the
Human Molecular Genetics Laboratory of the Center for
Molecular Biology and Genetic Engineering (CBMEG),
State University of Campinas (UNICAMP).
Survey and customization of tests
After a bibliographic search for genetic alterations re-
lated to hearing loss in different populations, 32 alter-
ations (Table 2) present in the population to be studied
were selected for the development of an OpenArray™
plate containing the assays.
The selected alterations were found in previous studies
realized at the Human Molecular Genetics Laboratory of
the Center for Molecular Biology and Genetic Engineer-
ing (CBMEG). Most of the selected changes were alter-
ations related with the hearing loss, affecting the protein
structure. But were selected two essays to detect the
large deletions in the GJB6 gene (rs11843171 and
rs144457142). The strategy was adopted in this case be-
cause the OpenArray™ can detect insertions or deletions
with only 6 bp. This strategy allowed checking if the
probes would or not bind with both alleles. If there were
bind in both alleles, could mean that there were not any
large deletions. If any probe did not bind, so some of the
deletions could be present.
The sequences (approximately 300–500 bp) cover-
ing these changes were taken from the database of
the National Center for Biotechnology Information
(NCBI - http://www.ncbi.nlm.nih.gov/) and Ensembl
(http://www.ensembl.org/index.html). The changeswere flagged, marked, and sent for customization
using FileBuilder software (Applied BioSystems).Sample preparation
The purity and concentration of the samples were checked
using a NanoDrop® 8000 spectrophotometer (Thermo Sci-
entific) and a Qubit® 2.0 fluorometer (Invitrogen),
respectively.
For the samples showing an A260/280 ratio between 1.7
and 2.0 and a concentration of 50 ng/μL, precisely 2 μL
of each individual sample to be analyzed was placed in a
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ray™ Master Mix, using a distribution pattern that
obeyed the manufacturer's instructions. The plate was
sealed and then given a spin at 1000 rpm for 10 seconds
to remove any bubbles present in the mixture.
Genotyping using the TaqMan® OpenArray™ Genotyping
Platform and validation
The samples, tips, and the OpenArray™ plate were
placed into the AccuFill® system, and the plates were
customized to provide an even distribution. A volume
of 33 nL was dispensed into each nano-well. After the
plates were stabilized with the immersion fluid in a glass
case (both items were provided in the kit accompanying
the plates), and then sealed with a photosensitive gum
for 2 minutes under ultraviolet light in the sealing sta-
tion. The reaction for the amplification of fragments was
performed in the Dual Flat Block GeneAmp® PCR Sys-
tem 9700 thermal cycler (Applied Biosystems), and the
cycling lasted approximately 4 hours. The plates were
placed in an OpenArray™ NT Cycler® for detection of
the emitted fluorescence. After capture of the signal, the
results were imported into TaqMan® Genotyper software
for interpretation of the results according to the graphs
of clusters generated (Figure 2).
The results were tabulated and were then validated
using techniques that had been previously established in
the same laboratory. The standards listed in Table 3
were used for validation of the tests.Figure 2 View of mutation assay p.M34T using the OpenArray™ plate
samples with the normal sequence for both alleles. The green cluster inclu
(heterozygous). The blue cluster represents homozygous mutants containin
blue squares corresponds to the fluorescence of the controls (NTC).Results
After selecting the OpenArray™ plate layout, a study was
performed using the 32 main mutations associated with
hearing loss in the Brazilian population (Table 2). The
test for mutation m.827A > G, present in the MT-RNR1
gene, showed problems during the customization pro-
cedure; the manufacturer had not added it to the Open-
Array™ plate required for the study, so as a result there
were only 31 assays available for each OpenArray™ plate.
In total, 376 samples were studied, obtained from 282
individuals with hearing loss and 94 normal controls. All
samples were analyzed in duplicate, searching for the
presence of previously selected alterations. Of the total,
367 samples had a good level of purity (A260/280 between
1.70 and 2.00) and a concentration of 50 ng/μL.
The number of samples studied was equivalent to four
OpenArray™ plates with the layout to analyze 32 assays
for 96 individuals (94 patients and two blank controls).
In total, 8 plates were used because all the analyses were
performed in duplicate to determine whether there were
any differences between the results obtained (no differ-
ences were observed).
For each OpenArray™ plate, 2,914 genotyping reactions
were performed, totaling 11,656 reactions in duplicate to
perform the genotyping of the 376 samples. Only nine
samples could not be analyzed (279 reactions, equivalent
to 2.39% of the total). A further 33 reactions (0.28%)
showed different results when compared with the previ-
ous results. The tests that were either considered invalidand TaqMan® Genotyper software. The red cluster represents
des individuals having one normal allele and one mutant allele
g both copies of the mutant alleles. The yellow region with the two
Table 3 Techniques used for validation of the assays
tested using the OpenArray™ plate
Gene Mutations analyzed Techniques
used to validate
GJB2 p.N206S; p.E147K; p.W24X,
c.167delT; c.235delC; p.V95M;
p.S113R; p.M93I; p.E129K; p.V37I;
p.L90P; p.R184P; p.W172X; p.R75Q;
p.M34T; p.V153I; p.K168R; c.35delG;
p.R184W
Direct sequencing
GJB6 c.6013G > T Multiplex PCR
miR96/183 c.13G > A; c.14C > A Direct sequencing
MT-RNR1
m.1555A > G RFLP-PCR
m.1494C > T RFLP-PCR
MT-TS1 m.7445A > G RFLP-PCR
SLC26A4 p.G149R; p.Q413R; p.V609G Direct sequencing
OTOF p.Q829X RFLP-PCR
TMC1 p.S647P Direct sequencing
CRYL1 c.1622 T > C Direct sequencing
Table 4 Changes detected on the OpenArray™ plates








c.35delG/ c.35delG 34 31
p.M34T/N 14 11
















c.35delG/N + p.V95M/N 3 3
c.35delG/N + p.V37I/N 2 2
c.35delG/N + p.R184P/N 2 2
c.35delG/N + p.W24X/N 2 2
c.35delG/N + c.167delT/N 2 2
c.35delG/N + p.V153I/N 1 1
c.35delG/N + p.L90P/N 1 1
p.V37I/N + p.V95M/N 2 2
p.V37I/N + c.167delT/N 1 1
p.M34T/N + p.N206S/N 1 1
p.M34T/N + p.R184W/N 1 1
p.V609G/N + p.E129K/N 1 1




MT-RNR1 m.A1555G 6 6
MT-TS1 m.A7445G 1 1
SLC26A4
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pairing corresponded to 39 reactions (0.33%).
Excluding the failed reactions and divergent results
(351 assays, equivalent to 3.01% of the total number
of assays), the reproducibility and accuracy were ob-
tained for 96.99% of the reactions (equivalent to 11,305
reactions). Studies of sensitivity and specificity of the
technique were performed having 0.97 and 0.98 as aver-
age values of these parameters, respectively.
The use of the TaqMan® OpenArray™ Genotyping Plat-
form helped in the genotyping of the selected mutations
in 196 samples (52.13% of the samples analyzed) for
whom there were no previously established genetic
results.
Among the 31 mutations analyzed in 376 samples, 179
changes were detected using the TaqMan® OpenArray™
Genotyping Platform. The results were validated for only
159 alterations, so that there was a discrepancy of 20
changes, classified as false positives and negatives
(Table 4).
The cost of genotyping using the TaqMan® OpenAr-
ray™ Genotyping Platform for a layout of 32 assays and
96 samples was $600 per plate. Given that it was pos-
sible to perform 2,914 reactions per plate, the cost of
each reaction would then be approximately $0.20.
Therefore, genotyping performed using the selected lay-
out would cost $6.40 per individual analyzed. In all, mu-
tations in 9 different genes were analyzed using this
genotyping platform. The values cited above refer only
to the kits used for genotyping. Other expenses, such as
the value of the equipment, skilled labor, and other re-
agents were not included in the calculations.
Martins et al. BMC Medical Genetics 2013, 14:112 Page 7 of 9
http://www.biomedcentral.com/1471-2350/14/112Discussion
The OpenArray™ genotyping plates showed high per-
formance, with the genotyping call average success rate
of 98.85%. This rate represents the amount of genotyp-
ing performed with success, in percentage, for OpenAr-
ray™ plate. But this value refers to the raw results,
including the false positives and negatives. After exclu-
sion of these tests that gave incorrect genotypes, the ac-
curacy rate of the selected layout was 96.99%.
The failed reactions could have been due to samples that
were degraded, less pure than recommended (A260/280
below 1.7), presented concentrations lower than 50 ng/μL,
do not respecting the minimum number of 250 copies of
haploid DNA required for the experiment.
False positives were detected in eight assays (Table 4),
as follows: c.35delG, p.M34T, p.V37I, p.V153I, p.E129K,
and p.W24X in the GJB2 gene, and p.V609G and p.
G149R in the SLC26A4 gene. All the tests mentioned
above were validated by direct sequencing, using an
established standard technique for analysis of the GJB2
and SLC26A4 genes at the Human Molecular Genetics
Laboratory of CBMEG/UNICAMP. These assays were
not excluded from the selected layout because some of
them are essential. Savings in terms of time and cost
could be achieved by only sequencing those samples that
showed mutations using the OpenArray™ plates, instead
of sequencing all patients in order to detect changes,
discarding the false positives.
The tests that showed false negatives concerned p.
V95M in the GJB2 gene and p.Q413R in the SLC26A4
gene. Heterozygosis samples for these assays were not
detected using the OpenArray™ plate, but were con-
firmed in the validation. However, two samples showed
compound heterozygous mutations for the changes p.
V37I and p.V95M, and the results were validated by dir-
ect sequencing. This last result did not exclude the pos-
sibility of a false negative, so the test should be either
redesigned or deleted from the chosen layout and re-
placed by another. In the case of the p.Q413R change,
even the positive control for the mutation was not de-
tected. This control was clustered together with the nor-
mal subjects, indicating that the test was unable to
detect this change. It would be necessary to consider al-
tering the probes and primers in this assay in order to
optimize the screening of this alteration. If unsuccessful,
it should be deleted from the selected layout and re-
placed by another assay, chosen following the same cri-
teria used to select the other tests.
The tests rs11843171 (c.6013G > T in the GJB6 gene)
and rs144457142 (c.1622 T > C in the CRYL1 gene) was
selected to try to detect the large GJB6 gene deletions,
but they were uninformative. Both SNPs (Single Nucleo-
tide Polymorphisms) were selected to detect the del
(GJB6-D13S1830) and/or del(GJB6-D13S1854) deletionsin the GJB6 gene. However, these tests failed to detect
the deletion of four selected cases (three cases of del
(GJB6-D13S1830) and one of del(GJB6-D13S1854)),
which could therefore be considered to be false nega-
tives. However, these SNPs were considered uninforma-
tive since the only conclusion that could be reached
using this assay would be the presence of a heterozygous
sample for one of the SNPs, indicating that the two dif-
ferent probes were paired where there could be dele-
tions. Hence, the individual would be deemed normal,
showing no large deletions in the GJB6 gene.
As reported in the literature, hearing loss is clinically and
genetically heterogeneous [37]. In this study, a prevalence
of c.35delG cases was detected, present as heterozygous
and homozygous forms or in combination with other
changes related to hearing loss (compound heterozygous
or homozygous). Given such heterogeneity, the search for
tools and technologies to perform the screening of major
mutations related to hearing loss in the population is in-
tensifying [15]. High-throughput platforms are the main
solution for simultaneous screening, as they are much fas-
ter compared to conventional molecular techniques used
to scan for large numbers of changes (ranging from one
change to thousands of changes).
Aspects of the OpenArray™ technology that make it an
excellent tool for use in molecular diagnosis is that the
plates already contain the assays in the nano-wells, only
requiring the addition of the properly quantified DNA
sample. Handling and distribution of the samples in the
OpenArray™ plate is performed by an auto-pipettor,
which increases the precision and decreases pipetting er-
rors. Furthermore, depending on the workflow layout, it
is possible to achieve up to around 99,000 genotyping
reactions per day. In practice, this scale of analysis is not
recommended, due to risks such as evaporation and ex-
change of samples. Another important point in relation
to cost is that compared to conventional genotyping
techniques (where tests are performed one at a time),
use of the platform is less expensive in terms of both re-
agents and manual labor.
The use of the high-throughput TaqMan® OpenArray™
Genotyping platform for diagnosis would greatly assist
in the initial screening of hearing loss of genetic origin,
since it enables the main changes to be evaluated, gener-
ating a greater number of results (simultaneously) in a
much shorter time compared to the same screening per-
formed using conventional techniques. It is also less ex-
pensive. An additional consideration is that after
optimization and standardization, the accuracy of the
technique (around 97%) would tend to increase due to
exchange of the tests that did not work correctly previ-
ously, hence optimizing the assays. Due to the genetic
heterogeneity of hearing loss, the ideal would be to use a
layout with a larger number of Assays (256 Assays for
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crease. Nevertheless, the technique still remains advan-
tageous because the simultaneous screening of 256
alterations can provide a greater number of outputs than
conventional techniques, with savings in terms of time
and cost.Conclusions
The TaqMan® OpenArray™ Genotyping Platform proved
to be highly effective for the genotyping of samples in
relation to hearing loss, with an accuracy rate of 96.99%,
equivalent to 11,305 reactions. The time required to per-
form the screening of 31 mutations was much lower
compared to detection by conventional techniques. Fur-
thermore, the OpenArray™ plates proved to be excellent
tools for reproducible diagnosis, since it was only neces-
sary to add the samples to the plate. However, the cor-
rect choice and standardization of assays was necessary.
The chosen layout presented two false negative assays
(p.V95M in the GJB2 gene and p.Q413R in the SLC26A4
gene), which were eliminated using a diagnostic proced-
ure. Eight false positive tests (c.35delG, p.M34T, p.V37I,
p.V153I, p.E129K, and p.W24X in the GJB2 gene, and p.
V609G and p.G149R in the SLC26A4 gene) were not dis-
carded because they are essential tests for the screening.
The rs11843171 (c.6013G > T in the GJB6 gene) and
rs144457142 (c.1622 T > C in the CRYL1 gene) tests se-
lected to study the del(GJB6-D13S1830) and del(GJB6-
D13S1854) deletions in the GJB6 gene were found to be
uninformative. However, no individuals heterozygous for
rs11843171 and rs144457142 were detected using the
OpenArray™ platform.
Analysis of the failed results showed that the high yield
and reproducibility of this technique were closely associ-
ated with the integrity of intact bands in the agarose gel,
purity (A260/280 between 1.7 and 2.0) and the sample
concentration (50 ng/μL).
Although it has been shown to be a promising tech-
nique, it has some important limitations to be described.
Among the most important are the inability to
customize some assays according to the predetermined
standards by the company, as the case studies involving
insertions and deletions where it is possible to analyze
small indels of up to 6 bp, and the impossibility of find-
ing new alterations, once the OpenArray™ assays are
mounted only with changes already reported or with the
known sequence. However, among the strengths of the
technique that made it so promising, are the low cost
and reduced time to carry out a large number of geno-
typing, the high accuracy rate, sensitivity, specificity and
the easy reproducibility compared to conventional tech-
niques of genotyping. All these points make the platform
layout suitable for possible applications involving thediagnosis of not only hearing loss, but also any disease
that has known genetic causes.
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